Cheaper competitor is trying to take Johnson & Johnson down

Johnson & Johnson could face a major cut in revenue now that pharmaceutical giant Merck and partner Samsung Bioepis are marketing their generic version of expensive medicine. Their products are nearly 35 percent less than nearly identical Johnson & Johnson drugs. While the products are similar to the original products, they're not exactly the same.